Longevity & Aging
resveratrol activates SIRT1
In plain terms: Does resveratrol switch on the longevity gene SIRT1?
Leans against Longevity & Aging 🔬 Includes disconfirming
Part of: 🧪 resveratrol
RefutedContestedStrong support
consensus score -0.42
Probably not — four independent labs showed the original finding was a lab-test quirk, only ever seen in the lab.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
7 support 21 contradict 4 tested null 18 mixed · 50 sources, 27 independent groups
What the evidence shows
The origin claim (Howitz/Sinclair 2003). Decisively challenged as a Fluor-de-Lys fluorophore-substrate ASSAY ARTIFACT by four independent groups (Kaeberlein, Denu, Pfizer, GSK) - resveratrol is not a direct activator of SIRT1 with native substrates.
The evidence (50)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Dai 2010 · J Biol Chem | in-vitro | mixed | moderate | Kinetic/biophysical evidence for direct STAC-SIRT1 interaction; activation seen but substrate/fluorophore dependence acknowledged |
| Chung 2012 · Adipocyte | observational | contradicts | moderate | Review: resveratrol metabolic effects stem from PDE4 inhibition raising cAMP/AMPK; rolipram reproduces benefits, SIRT1 not the direct target |
| Niu 2025 · Curr Protoc | in-vitro | tested-null | low | Nucleosome-substrate deacylation kinetics: native NCP platform for activator EC50 shows peptide assays overstate modulator potency vs chromatin |
| Manna 2018 · J Mol Model | mechanism | supports | low | Computational study models direct dihydropyridine/STAC binding driving SIRT1 conformational activation - mechanistic support for direct activation |
| Matysek 2023 · Ageing Res Rev | meta-analysis | contradicts | moderate | Systematic review of sirtuin-pathway compounds for dementia found sparse, inconsistent human evidence of SIRT1-attributable resveratrol/STAC benefit |
| Park 2012 · Cell | animal | contradicts | high | Metabolic benefits arise from cAMP-PDE inhibition raising cAMP to activate Epac1/AMPK; SIRT1 activation is downstream/indirect, not direct |
| Milne 2007 · Nature | in-vitro | mixed | high | Sirtris STACs 1000x more potent than resveratrol bind allosteric N-terminal site, lower Km for acetylated substrate; activation allosteric/substrate-linked |
| Hubbard 2013 · Science | in-vitro | contradicts | high | Identifies SIRT1 Glu230 allosteric site; STACs activate SIRT1 with specific hydrophobic substrate motifs (e.g. PGC-1a) - not pure assay artifact |
| Price 2012 · Cell Metab | animal | mixed | high | Inducible SIRT1-KO abolishes moderate-dose resveratrol AMPK/mito benefits (SIRT1-dependent) but high-dose acts SIRT1-independently; dose-critical, not direct |
| Liu 2023 · Protein Cell | in-vitro | mixed | moderate | Review: SIRT1 activation by STACs is real but N-terminal-domain allosteric and substrate-sequence dependent, not universal direct activation |
| Brenner C 2022 · Life Metab | mechanism | contradicts | moderate | Argues original yeast Sir2 longevity/STAC framing was artifact-driven; rejects sirtuins as conserved longevity genes behind resveratrol-SIRT1 story |
| Howitz 2003 · Nature | in-vitro | supports | moderate | Origin claim: resveratrol lowers SIRT1 Km, stimulates p53 deacetylation, extends yeast lifespan 70% |
| Scisciola 2020 · Epigenetics | in-vitro | tested-null | low | Novel non-fluorophore SIRT1 activators (SCIC2) enhance deacetylase activity on native targets; frames resveratrol effect as scaffold-limited |
| Cai 2015 · Sci Transl Med | animal | contradicts | high | Low dietary-dose resveratrol beat 200x higher dose via AMPK/mTOR/autophagy not dose-escalating SIRT1; non-linear PK argues against simple direct activation |
| Manjula 2020 · Front Pharmacol | observational | mixed | low | Review: resveratrol SIRT1 activation is allosteric and conformation-dependent, effective only for select substrates |
| Fiorentino 2025 · Med Res Rev | observational | mixed | moderate | Review concludes resveratrol is a genuine but weak, substrate-selective SIRT1 activator - reconciles artifact critique with allosteric evidence |
| Li 2017 · Sci Rep | animal | mixed | moderate | Resveratrol suppressed anaphylaxis via SIRT1-downstream AMPK axis; framed as SIRT1 working through AMPK rather than direct enzymatic activation |
| Malospirito 2025 · Proteins | mechanism | tested-null | low | Models SIRT1 N-terminal 3-helix bundle as substrate-anchoring interface; supports allosteric NTD activation but substrate-anchoring-dependent |
| Patel 2010 · Cancer Res | observational | contradicts | moderate | Clinical PK: colorectal tissue reaches 674 nmol/g but plasma parent compound low, dominated by conjugates, limiting systemic direct SIRT1 engagement |
| Cao 2015 · Genes Dev | in-vitro | contradicts | high | Crystal structure: three resveratrol molecules mediate SIRT1 N-terminal binding to a coumarin peptide - structural basis for substrate-dependent activation |
| Orlandi 2017 · Redox Biol | in-vitro | supports | moderate | In yeast chronological aging resveratrol shortens lifespan Sir2-dependently; effect does not translate to proposed pro-longevity SIRT1 activation |
| Bursch 2024 · Molecules | mechanism | mixed | moderate | Activator review: direct SIRT1 activation by resveratrol is substrate-selective and assay-sensitive; cautions against fluorogenic-only evidence |
| You 2019 · Sci Rep | in-vitro | mixed | moderate | Crystal structures show quercetin allosterically activates SIRT6 via a defined pocket; structural precedent for polyphenol allosteric activation |
| Nguyen 2013 · Chem Biol | in-vitro | mixed | moderate | Crystal structures show 4'-bromo-resveratrol binds two SIRT3 sites; supports an allosteric site model relevant to SIRT1 activation |
| Baur 2006 · Nature | animal | mixed | high | Resveratrol shifts high-cal-diet mice toward healthy phenotype with raised AMPK/PGC-1a and SIRT1-pathway changes; consistent with but not direct activation |
| Kaeberlein 2005 · J Biol Chem | in-vitro | contradicts | high | Resveratrol activates Sir2/SIRT1 only on Fluor-de-Lys fluorophore-tagged peptides; no in-vivo Sir2 effect in 3 yeast backgrounds |
| Cuyas 2018 · Front Endocrinol | mechanism | mixed | low | Computational+experimental: metformin docks SIRT1 N-terminal autoinhibitory region as direct STAC; supports allosteric-site model, non-resveratrol |
| Yoshino 2012 · Cell Metab | RCT | contradicts | high | 12wk 75mg/d resveratrol in non-obese women: no metabolic benefit, no change in putative targets AMPK, SIRT1, NAMPT or PGC-1a in muscle or adipose |
| Chen 2019 · J Comput Aided Mol Des | mechanism | mixed | moderate | MD/MM-GBSA of 3-resveratrol SIRT1 complex: two stabilize substrate binding, third weakly bound; supports substrate-bridging not direct activation |
| Borra 2005 · J Biol Chem | in-vitro | contradicts | high | [FT-verified] Borra: ~8x activation only with covalently-attached fluorophore - the artifact source |
| Hou 2016 · Sci Rep | mechanism | mixed | moderate | MD + fragment mapping: resveratrol is a substrate-specific interaction stabilizer at N-terminal domain, activating only loose-binding substrates |
| Beher 2009 · Chem Biol Drug Des | in-vitro | contradicts | high | [FT-verified] Beher: Fluor-de-Lys artificial substrate, no activation on p53 peptide |
| Timmers 2011 · Cell Metab | RCT | mixed | high | 30d resveratrol in obese men raised muscle SIRT1/PGC-1a protein and AMPK with CR-like effects; markers up but cannot show direct enzyme activation |
| Liu 2020 · Phys Chem Chem Phys | mechanism | mixed | moderate | Multiscale free-energy model: FdL fluorophore and native hydrophobic residues only weakly correlated in driving SIRT1 activation by resveratrol |
| Ma 2017 · Oxid Med Cell Longev | animal | supports | moderate | Resveratrol alleviated diabetic cardiomyopathy via SIRT1-mediated mitochondrial regulation; no SIRT1-loss control to prove direct mechanism |
| Goh 2014 · Int J Sport Nutr Exerc Metab | RCT | supports | moderate | Resveratrol in T2DM raised skeletal-muscle SIRT1 expression and AMPK; expression rise attributed to SIRT1 but not direct enzyme activation |
| Gertz 2012 · PLoS One | in-vitro | supports | moderate | Resveratrol directly modulates sirtuins (activates SIRT1/SIRT5, inhibits SIRT3) via a fluorophore-dependent mechanism - effect is substrate-conditional |
| Curry 2021 · Front Physiol | observational | contradicts | moderate | Review: resveratrol direct SIRT1 activation confounded by fluorophore assays; few STACs reached clinic, underscoring weak direct-activation case |
| Pacholec 2010 · J Biol Chem | in-vitro | contradicts | high | [FT-verified] Pacholec: resveratrol+SRT1720 fail to activate SIRT1 with native substrate |
| Baksi 2014 · Br J Clin Pharmacol | RCT | contradicts | moderate | Phase II SRT2104 (selective SIRT1 activator) in T2DM gave no significant glycaemic improvement; clinical SIRT1-activation translation underwhelming |
| Pezzuto 2019 · Biomol Ther | mechanism | contradicts | moderate | 20-year review: resveratrol overtly promiscuous with elusive dominant mechanism; SIRT1 as the defining direct target not supported |
| Shao 2019 · Redox Biol | in-vitro | contradicts | high | RAMSSAY mass-spec assay with biotin-acetyl-p53 peptide: resveratrol, SRT1720, S17834 all failed to activate endogenous SIRT1 on native substrate |
| Nin 2012 · J Biol Chem | in-vitro | contradicts | moderate | SIRT1 acutely activated in cells by AMPK/PKA-driven dissociation from inhibitor DBC1 without NAD+ change; endogenous activation is indirect |
| Walle 2004 · Drug Metab Dispos | in-vitro | contradicts | high | Oral resveratrol well absorbed but near-zero bioavailability (<5 ng/mL unchanged); free plasma far below in-vitro SIRT1-activating doses |
| Zhang 2021 · Commun Biol | in-vitro | supports | high | With native non-fluorogenic Ac-p53 peptide resveratrol raised SIRT1-substrate affinity only 1.4x (vs 8.2x KPMF-8); near-null on native substrate |
| Scribbans 2014 · Appl Physiol Nutr Metab | RCT | contradicts | moderate | Resveratrol with HIIT lowered training-induced PGC-1a/SIRT1/SOD2 gene expression vs placebo, blunting rather than activating the SIRT1 axis |
| Hoffmann 2013 · Br J Clin Pharmacol | RCT | mixed | moderate | First-in-class selective SIRT1 activator SRT2104 tolerable with defined PK; Sirtris built dedicated activators as resveratrol's direct action was unreliable |
| Minor 2011 · Sci Rep | animal | tested-null | low | Synthetic SIRT1 activator SRT1720 extends obese-mouse lifespan; mito effects SIRT1/PGC-1a-dependent (conditional KO), a purpose-built target vs resveratrol |
| Dai 2015 · Nat Commun | in-vitro | mixed | high | Crystal structure of mini-hSIRT1-STAC complex shows direct activator binding to the N-terminal domain - direct activation mechanism, not artifact |
| Beijers 2020 · Clin Nutr | RCT | contradicts | moderate | 4wk resveratrol in COPD did not improve muscle mitochondrial function or alter SIRT1-pathway/inflammatory gene expression vs placebo |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.